Names | |
---|---|
IUPAC name
3β,5-Dihydroxy-14,15-epoxy-5β,14β-bufa-20,22-dienolide
| |
Systematic IUPAC name
5-[(1R,2aR,3aS,3bR,5aS,7S,9aR,9bS,11aR)-5b,7-Dihydroxy-9a,11a-dimethylhexadecahydronaphtho[1′,2′:6,7]indeno[1,7a-b]oxiren-1-yl]-2H-pyran-2-one | |
Other names
Marinobufagin, Marinobufagenin
| |
Identifiers | |
3D model (
JSmol)
|
|
ChemSpider | |
PubChem
CID
|
|
UNII | |
CompTox Dashboard (
EPA)
|
|
| |
| |
Properties | |
C24H32O5 | |
Molar mass | 400.515 g·mol−1 |
Hazards | |
Occupational safety and health (OHS/OSH): | |
Main hazards
|
Toxic |
Except where otherwise noted, data are given for materials in their
standard state (at 25 °C [77 °F], 100 kPa).
|
Marinobufagenin (marinobufagin) is a cardiotonic bufadienolide steroid. It can be found in the plasma and urine of human subjects with myocardial infarction, kidney failure, and heart failure. [1] It is also secreted by the toad Bufo rubescens [2] and other related species such as Bufo marinus. It is a vasoconstrictor with effects similar to digitalis. [3]